Edesa Biotech (EDSA) Net Equity Issued and Repurchased (2020 - 2025)

Edesa Biotech has reported Net Equity Issued and Repurchased for 6 years, with the latest figure at $3.5 million in Q4 2025.

• Quarterly Net Equity Issued and Repurchased rose 458.08% year-over-year to $3.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.6 million (up 917.22% YoY) and the FY2025 annual result came in at $7.7 million, up 958.1% from the prior year.
• Net Equity Issued and Repurchased grew to $3.5 million in Q4 2025 per EDSA's latest filing, from $220501.0 in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $20.0 million in Q1 2023 and troughed at -$1.3 million in Q1 2022.
• A 5-year average of $2.8 million and a median of $483772.0 in 2023 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2021 and 2022: Net Equity Issued and Repurchased plunged 122.94% in 2021, then surged 298942275.0% in 2022.
• Over 5 years, Net Equity Issued and Repurchased stood at $1.3 million in 2021, then surged by 135.21% to $3.0 million in 2022, then tumbled by 89.59% to $315201.0 in 2023, then surged by 98.84% to $626760.0 in 2024, then soared by 458.08% to $3.5 million in 2025.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $3.5 million, $220501.0, and $6.9 million for Q4 2025, Q3 2025, and Q1 2025 respectively.